Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

BACKGROUND: In the HIV-1 vaccine trial RV144, ALVAC-HIV prime with an AIDSVAX(®) B/E boost reduced HIV-1 acquisition by 31% at 42 months post first vaccination. The bivalent AIDSVAX(®) B/E vaccine contains two gp120 envelope glycoproteins, one from the subtype B HIV-1 MN isolate and one from the sub...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:PLoS One
Huvudupphovsmän: Gilbert, Peter B., Excler, Jean-Louis, Tomaras, Georgia D., Carpp, Lindsay N., Haynes, Barton F., Liao, Hua-Xin, Montefiori, David C., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Kijak, Gustavo H., Tovanabutra, Sodsai, Francis, Donald P., Lee, Carter, Sinangil, Faruk, Berman, Phillip W., Premsri, Nakorn, Kunasol, Prayura, O’Connell, Robert J., Michael, Nelson L., Robb, Merlin L., Morrow, Rhoda, Corey, Lawrence, Kim, Jerome H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Public Library of Science 2017
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5426618/
https://ncbi.nlm.nih.gov/pubmed/28493891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0176428
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk